Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 81 - 100 out of 500 displayed.
«  1  2  3  4 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
Reset 

ImaginAb Reconstitutes Japanese Subsidiary

LOS ANGELES and TOKYO, June 22, 2018 /PRNewswire/ -- ImaginAb, Inc. announced today new directors of ImaginAb Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc. Headquartered in Tokyo, the subsidiary's goal is to better realize partnering opportunities with Japanese pharmaceutical... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  ImaginAb, Inc.

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  U.S. Food and Drug Administration | IMPEL NEUROPHARMA INC.

Lilly Completes Acquisition of ARMO BioSciences

INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of ARMO BioSciences, Inc. (NASDAQ: ARMO).

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  Armo BioSciences, Inc. | Eli Lilly and Company

Righttime Medical Care and HeadFirst Concussion Care Welcome Chesapeake Neurology Associates

ANNAPOLIS, Md., June 22, 2018 /PRNewswire/ -- Rightime Medical Care is pleased to announce that renowned Maryland-based neurologist Harry G. Kerasidis, M.D., and his team at Chesapeake Neurology Associates have joined the urgent care company's HeadFirst Sports Injury and Concussion Care program.... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018

GPB Capital Enters into $21 Million Debt Investment in CardioFocus®

NEW YORK, June 22, 2018 /PRNewswire/ -- GPB Capital has completed a debt investment in CardioFocus® Inc., which develops and manufactures products for the treatment of irregular heartbeats and other cardiac disorders. Proceeds from the investment will help CardioFocus commercially launch its... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  CardioFocus, Inc.

Canadian Cannabis Legalization Helps to Deter Illegal Markets

NEW YORK, June 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018

William A. Haseltine, PhD Joins Grace Therapeutics' Board of Directors

EAST BRUNSWICK, N.J., June 22, 2018 /PRNewswire/ -- Grace Therapeutics, a clinical stage biopharmaceutical company focused on rare and orphan diseases, announced today that William Haseltine has been appointed to the company's Board of Directors. Dr. Haseltine is currently Chairman and President... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018

Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)

HANOVER, Md., June 22, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that the U.S. Food and Drug Administration... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  Processa Pharmaceuticals Inc.

Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors

INCLINE VILLAGE, Nev., June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth G. O'Farrell has been named to the Company's Board of Directors, effective June 22, 2018 and increasing the number... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018

Proteomics International at American Diabetes Association 78th Scientific Sessions following new license deals for diabetic kidney disease predictive test in USA and Mexico

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has just signed license agreements for its world-leading PromarkerD predictive test for diabetic kidney disease with USA and Mexico partners.

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018

Global CNS Therapeutics Markets, 2024: Awareness Campaigns Launched by Pharma Companies to Benefit the Market

DUBLIN, June 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018

Sinus Dilation Devices Market to Grow at 9.1% Annual Growth Rate - Premium Insights (2018 to 2022)

PUNE, India, June 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018

Prometic Presents New Data on NASH Drug Candidate PBI-4547

LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announced the presentation of four posters at the American Diabetes Association's 78(th) Scientific Sessions taking... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  ProMetic Life Sciences Inc. | ProMetic Life Sciences Inc.

Beleave Applauds Canadian Leadership and Continued Progress of Cannabis Legalization

TORONTO, June 22, 2018 /CNW/ - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") would like to commend the outstanding leadership, tenacity, and bravery of the Canadian government in passing Bill C-45 into law. As the first G7 country to legalize cannabis, this... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  Beleave Inc.

Canopy Growth Corporation Announces Exercise and Closing of Over-Allotment Option

SMITHS FALLS, ON, June 22, 2018 /PRNewswire/ - Canopy Growth Corporation (TSX: WEED) (NYSE:CGC) ("Canopy Growth" or the "Company") announced today the issuance of C$100 million aggregate principal amount of its 4.25% convertible senior notes due 2023 (the "Over-Allotment Notes") pursuant to the... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018

Whisk's AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

BASEL, Switzerland and ORLANDO, Florida, June 22, 2018 /PRNewswire/ -- Today, at the American Diabetes Association's 78(th) Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global... Read more ››

By: PR Newswire Association LLC. - 22 Jun 2018
Related companies:  Ascensia Diabetes Care Holdings AG

Shire plc: Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas

Read more ››
By: Nasdaq / GlobenewsWire - 22 Jun 2018

Shire plc : Rule 2.9 Announcement

Read more ››
By: Nasdaq / GlobenewsWire - 22 Jun 2018

DSM Finalizes Repurchase of Shares to Cover Existing Option Plans and Stock Dividends

HEERLEN, Netherlands, June 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018

NICE Recommends Sanofi's New Treatment Dupixent(R)     (dupilumab) for Adults with Moderate to Severe Atopic Dermatitis in England[1]

GUILDFORD, England, June 22, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 22 Jun 2018
«  1  2  3  4 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »
to the top ↑